** Shares of U.S. drugmaker Eli Lilly LLY.N rise 2% to $859.99 premarket
** Co forecasts 2025 EPS between $22.50 and $24.00, above Street estimates of $22.86 at midpoint, according to data compiled by LSEG
** Co posts Q4 adj EPS of $5.32 vs estimates of $4.95, according to data compiled by LSEG
** Q4 sales of weight-loss drug Zepbound came in at $1.91 billion vs estimates of $2.03 billion -LLY
** Up to last close, stock gained 19.5% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。